To view this email as a web page, click here

Today's Rundown

Featured Story

Johnson & Johnson's D.C. incubator opens for business with diversity at its core

The pandemic wasn’t going to slow JLABS down. Two years after announcing a new location, Johnson & Johnson’s incubator arm opened its doors in the nation’s capital on Monday, right on time. 

read more

Top Stories

AstraZeneca and Sanofi's antibody prevents RSV in phase 3, accelerating path to market

AstraZeneca and Sanofi’s nirsevimab has protected healthy babies against respiratory syncytial virus disease in a phase 3 clinical trial. The earlier-than-expected readout will enable a 2022 filing for a monoclonal antibody Sanofi CEO Paul Hudson has hailed as a “massive opportunity.”

read more

FDA lifts clinical hold on uniQure's gene therapy amid cancer concerns; shares jump

After four months of hand-wringing and a deep investigation into how a patient was diagnosed with cancer after getting uniQure’s hemophilia gene therapy, the FDA is allowing the trial to continue.

read more

Sponsored: Look before you leap: How a joined-up development strategy pays off for early-stage biotechs

A well-thought-out strategic development plan that brings together nonclinical, clinical, regulatory and commercial experts can improve efficiencies, cut costs, shorten timelines, and increase the chances of success for a new drug program.

read more

Vertex picks a horse in race for opioid painkiller replacement

Boston-based Vertex says its NaV1.8 inhibitor VX-548 will advance to a phase 2 clinical trial after a successful phase 1 safety trial.

read more

I-Mab's IL-6 drug hits goal in ulcerative colitis phase 2

A phase 2 trial of I-Mab’s olamkicept in ulcerative colitis patients has met its primary endpoint. The study provides early evidence that the IL-6 inhibitor improves outcomes including rectal bleeding. 

read more

FDA says Voyager can trek on as it removes trial hold for Huntington's gene therapy test

The FDA is in a forgiving mood: After clearing uniQure’s gene therapy to restart trials today, it’s handing the same reprieve to Voyager Therapeutics.

read more

Medtronic taps virtual reality 'flight simulators' for brain surgery, built from 3D patient scans

Using virtual reality tech described as a fighter-jet flight simulator for the human body, Medtronic hopes to put brain surgeons in the pilot’s seat—giving them patient-specific maps of blood vessels and tissue to explore as they prep for the real thing.

read more

ADC Therapeutics scores FDA approval for anti-CD19 blood cancer med Zynlonta

Multiple new CAR-T medicines against diffuse large B-cell lymphoma have hit the market in recent years, improving prospects for patients and extending the array of available options for doctors. Now, with an FDA approval Friday afternoon, ADC Therapeutics is getting ready to launch the first single-agent CD19-targeted antibody-drug conjugate therapy against the disease.

read more

Resources

Article: Make the right move at every step of the drug commercialization process

Developing a quality product and getting it approved for distribution is not enough to guarantee commercial success.

eBook: The New Standard: Virtual Study Training in Clinical Trials

The new standards in study training help sponsors and CROs reduce costs by 60%, cut training time by 50%, and start enrollment 55 days faster – learn more today.

Report: New research indicates an accelerated shift to decentralized clinical trials

New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19.

Content Hub: Process Intensification Resource Center

A one-stop hub for Cytiva resources to support process intesification

Whitepaper: COVID-19 Survey report: The Lasting Impact on Outsourcing Decisions

How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond?

Content Hub: Emerging Biotech Resource Center

A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule

Whitepaper: Top 5 Benefits of a Cloud ELN

Discover the benefits of a cloud-native ELN that delivers better performance, security, connectivity, total cost of ownership PLUS sub-second search results through even the largest data volumes.

Special Report: The Marketer’s Guide to Taking the Vaccine Viral

Access this guide for the latest insights into how marketers can use data, technology, and personalized messaging to build vaccine confidence and drive successful immunization efforts.

Content Hub: How to improve the virtual work you do every day

We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met.

Whitepaper: Roche to pick up GenMark Diagnostics in $1.8B infectious disease testing deal

Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously.

Content Hub: Remarque Systems Resource Hub

Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. 

Whitepaper: New Data: A Better Way to Run CHO Cell Culture Experiments

Find out how upstream bioprocess scientists can use Culture Biosciences’ bioreactor system and real-time data visualizations to get faster insights and get their product to market more quickly.

Whitepaper: Overcoming the hurdles of Real-World Data Access through a federated global network

Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights.

Report: New research indicates an accelerated shift to decentralized clinical trials

New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19.

Executive Summary: Manufacturing Strategies to Effectively Industrialize Autologous Cell Therapies

Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

eBrief: Drug Product Process Development: Ensuring a Consistent, High-quality Biologic

Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase.

Whitepaper: Achieving a Successful Drug Product Technology Transfer

Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent.

Whitepaper: The Art of Recognizing Clinical Supply Risk Factors

In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management.

eBook: Expecting the Unexpected: Strategies for Efficient Clinical Supply Management and Forecasting

Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study.

Events